270 related articles for article (PubMed ID: 38796455)
1. Advances in nano-immunotherapy for hematological malignancies.
Xu J; Liu W; Fan F; Zhang B; Sun C; Hu Y
Exp Hematol Oncol; 2024 May; 13(1):57. PubMed ID: 38796455
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
3. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
Yangjie L; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38213150
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective.
Allegra A; Gioacchino MD; Tonacci A; Petrarca C; Gangemi S
Nanomaterials (Basel); 2021 Oct; 11(11):. PubMed ID: 34835555
[TBL] [Abstract][Full Text] [Related]
6. Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.
Li YR; Halladay T; Yang L
J Biomed Sci; 2024 Jan; 31(1):5. PubMed ID: 38217016
[TBL] [Abstract][Full Text] [Related]
7. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
8. A new perspective on hematological malignancies: m6A modification in immune microenvironment.
Yang S; Xu L; Zhuang H; Li F; Lu Y
Front Immunol; 2024; 15():1374390. PubMed ID: 38868768
[TBL] [Abstract][Full Text] [Related]
9. Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.
Ku KS; Tang J; Chen Y; Shi Y
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791398
[TBL] [Abstract][Full Text] [Related]
10. Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology.
Bockamp E; Rosigkeit S; Siegl D; Schuppan D
Cells; 2020 Sep; 9(9):. PubMed ID: 32942725
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
Zuo YH; Zhao XP; Fan XX
Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
[TBL] [Abstract][Full Text] [Related]
12. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
[TBL] [Abstract][Full Text] [Related]
14. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
[TBL] [Abstract][Full Text] [Related]
15. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
[TBL] [Abstract][Full Text] [Related]
16. CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies.
Faeq MH; Al-Haideri M; Mohammad TAM; Gharebakhshi F; Marofi F; Tahmasebi S; Modaresahmadi S
Med Oncol; 2023 Apr; 40(5):155. PubMed ID: 37083979
[TBL] [Abstract][Full Text] [Related]
17. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
[TBL] [Abstract][Full Text] [Related]
18. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
[TBL] [Abstract][Full Text] [Related]
20. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]